Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
C$10.60
-3.8%
C$10.60
C$3.50
C$15.75
C$168.68MN/A12,671 shs3,402 shs
Biopharmx Corp stock logo
BPMX
Biopharmx
$0.00
$0.25
$6.30
$111.86MN/A2.15 million shs336,508 shs
Hemostemix Inc. stock logo
HEM
Hemostemix
C$0.14
C$0.11
C$0.04
C$0.43
C$20.40M0.2413,602 shs81,445 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$16.52
-1.4%
$14.79
$2.80
$8.97
$595.68M0.6337,931 shs881,491 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00%0.00%0.00%0.00%0.00%
Biopharmx Corp stock logo
BPMX
Biopharmx
0.00%0.00%0.00%0.00%0.00%
Hemostemix Inc. stock logo
HEM
Hemostemix
0.00%+3.70%+12.00%+33.33%+133.33%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%-9.23%+19.54%+29.06%+81.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00
N/AC$15.0041.51% Upside
Biopharmx Corp stock logo
BPMX
Biopharmx
0.00
N/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
0.00
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AC$3.34 per share3.17C$3.60 per shareN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AC$0.01 per share10.77C($0.10) per shareN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A-C$0.38N/AN/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
-C$5.00M-C$0.03N/AN/AN/A37.07%-349.24%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.05
129.63
128.68
Biopharmx Corp stock logo
BPMX
Biopharmx
N/AN/AN/A
Hemostemix Inc. stock logo
HEM
Hemostemix
-55.07
0.04
0.48
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A
Biopharmx Corp stock logo
BPMX
Biopharmx
N/A
Hemostemix Inc. stock logo
HEM
Hemostemix
10.43%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
515.91 millionN/ANot Optionable
Biopharmx Corp stock logo
BPMX
Biopharmx
1718.28 millionN/ANot Optionable
Hemostemix Inc. stock logo
HEM
Hemostemix
N/A145.73 millionN/ANot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
10 Fun Facts About Mountain Gorillas
ARS Pharmaceuticals Inc (SPRY)
Wild Isles
A look back at RNA Therapeutics – day one
SPRY ARS Pharmaceuticals, Inc.
FDA accepts ARS Pharma’s NDA for Neffy
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

New MarketBeat Followers Over Time

Media Sentiment Over Time

BriaCell Therapeutics stock logo

BriaCell Therapeutics CVE:BCT

C$10.60 -0.42 (-3.81%)
As of 12/30/2021

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Biopharmx stock logo

Biopharmx NYSEAMERICAN:BPMX

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Hemostemix stock logo

Hemostemix CVE:HEM

C$0.14 0.00 (0.00%)
As of 07/4/2025 10:34 AM Eastern

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$16.52 -0.23 (-1.37%)
As of 07/3/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.